Harlan Robins reported sales of common stock under Form 144, indicating dispositions of 100,000 and 10,000 shares. The filing notes the securities were acquired as Performance Awards on 03/07/2026. Transaction proceeds shown are $1,737,460 and $148,323.94.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 5,000 shares of common stock at $19.00 per share on June 11, 2026. After this transaction, she directly holds 411,775 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.
Harlan Robins submitted a Rule 144 notice to sell 10,000 shares of Common Stock on 04/08/2026.
The filing also lists recent compensatory issuances: 47,504, 41,246, and 11,250 shares were recorded as "Acquired as compensation -- Performance Awards" on 03/07/2026. A header line shows 160,044,392 shares with an associated date of 06/15/2026 as a contextual figure.
Adaptive Biotechnologies plans a private offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million, and intends to use proceeds for capped call transactions, up to $25 million of share repurchases and repayment of its OrbiMed revenue interest agreement.
The company is also pursuing a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, aiming to choose a preferred path by year-end 2026. MRD has grown revenue from $103 million in 2023 to $212 million in 2025 and reported $15 million of 2025 adjusted EBITDA, while Immune Medicine has built a large immune-receptor dataset and discovery platform.
ADPT filed a Form 144 notice listing a proposed sale of 5,000 shares of Common stock through Morgan Stanley Smith Barney LLC with a listed value of $85,350 and an associated date of 06/11/2026.
The filing also discloses recent 10b5-1 sales by Susan Bobulsky of 11,000 shares on 06/04/2026 for $198,000. The excerpt lists 160,044,392 shares outstanding as of 06/11/2026 as a context figure.
Adaptive Biotechnologies Corporation reported the results of its annual shareholder meeting held on June 5, 2026. Shareholders voted on electing two Class I directors, an advisory say-on-pay proposal, and ratifying the independent auditor.
Robert Hershberg received 93,188,652 votes for, or 71.81% of votes on the proposal, with 36,573,708 votes withheld and 13,570,859 broker non-votes. Katey Owen received 126,803,695 votes for, or 97.72%, with 2,958,666 votes withheld and the same broker non-votes.
The advisory vote on 2025 named executive officer compensation passed with 125,287,618 votes for (96.55%), 4,316,144 against, and 158,599 abstentions, plus 13,570,859 broker non-votes. Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 passed with 142,609,643 votes for (99.50%), 484,798 against, and 238,779 abstentions.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock. On June 4, 2026, Lo exercised options covering 19,521 shares at strike prices ranging from $3.99 to $12.14 per share, receiving an equivalent number of common shares.
On the same date, Lo completed an open-market sale of 39,741 Common Stock shares at an average price of $17.49 per share. Following these transactions, Lo holds 250,934 Common Stock shares directly and 2,500 shares indirectly through a spouse. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 11,000 shares of Common Stock at $18.00 per share. After the transaction, she directly holds 416,775 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025.
ADPT filed a Form 144 disclosing proposed sales of equity tied to prior awards. The filing lists 10,000 shares from previously exercised stock options dated 01/25/2022 and 1,000 restricted stock units dated 03/04/2022. The filing also reports 41,338 shares sold during the past three months for $544,421.46. The report identifies Morgan Stanley Smith Barney LLC as the broker-dealer and provides an address for the reporting person, Susan Bobulsky.
ADPT affiliate filed a Form 144 to sell common stock. The notice lists planned sales tied to an exercise of stock options on 06/04/2026 for 21,865 shares and restricted stock units dated 03/04/2025 for 20,220 shares. Recent Rule 10b5-1 sales in the past three months total 91,231 shares across dates in 03/2026 and 04/08/2026, with aggregate proceeds reported in the filing.